Family Navigates High Cost of Alzheimer's Drug After Slowing Husband's Decline
A couple shares their experience with a new Alzheimer's medication that has significantly slowed their husband's cognitive decline, while highlighting the substantial out-of-pocket costs.
Nick, 56, began exhibiting early signs of dementia, which his wife initially overlooked. He started asking how to spell words, a deviation from his usual strong spelling skills, and forgot recent events. These subtle changes prompted the couple to seek medical evaluation.
Blood and urine tests, along with brain scans, confirmed Nick had young-onset Alzheimer’s disease. He is one of an estimated 70,000 Britons living with the condition. While Nick was prescribed donepezil by the National Health Service (NHS), he could not tolerate the highest, most effective dose due to its potential to slow his heart rate, a concern for him as a lifelong runner.
The couple discovered Lecanemab, a drug that has shown promise in slowing the progression of Alzheimer's. Despite its effectiveness in slowing Nick’s cognitive decline and allowing them to resume aspects of their life together, the medication comes with a significant price tag, reportedly costing £80,000 annually. This has led to the couple paying a substantial amount out-of-pocket for treatment not yet offered by the NHS.
